Biomarkers

APOEε4 carriership combined with Aβ positivity for AD clinical trial enrichment

Potential value of p-tau181 and NfL for clinical trial pre-screening

Challenges in designing clinical trials for dementia with Lewy bodies

Biomarkers for early detection of Alzheimer’s disease: microRNAs

Systemic inflammation and reduced cerebral Aβ clearance triggered by pancreatic amylin

Plasma versus neuroimaging biomarkers for Alzheimer’s disease clinical trials

Targeting neuroinflammation: identifying new targets using transcriptomics

Developing novel digital biomarkers

Biomarkers of delirium incidence and severity

Successful Aging after Elective Surgery: goals of the SAGES II study

State of microglial and inflammatory markers in the AD field

Biomarkers for risk assessment and early diagnosis of AD

Next steps in dementia biomarkers

Neuropsychiatric and behavioral markers of dementia risk

Directions for blood biomarker research for early AD diagnosis

Progress in the Davos Alzheimer’s Collaborative’s Global Cohort Development program